View in browser Key highlights from 2021 SenzaGen experienced another busy year in 2021 continuing to work to advance our vision of replacing animal testing with innovative methods better suited to reflect human biology. Here is a snapshot of important events from this year. SenzaGen and VitroScreen joined forces The highly accurate and broadly applicable skin sensitization test platform GARD was joined by a recognized pre-clinical CRO and leading in vitro research laboratory. By joining forces, SenzaGen and VitroScreen provide a broadened in vitro service portfolio ranging from innovative in vitro toxicology to pre-clinical efficacy testing. Stay tuned for more information about our journey ahead! Read more Positive ESAC opinion on GARDskin In July, the ESAC issued a positive opinion on the GARDskin test method and recommended that the OECD includes the assay on their list of internationally agreed test methods, a major milestone in the regulatory approval process for the GARD technology. Read more GARD included in ISO 10993-10:2021 The new standard for skin sensitization ISO 10993-10 is freshly published and now includes in vitro methods. Our GARD assay is included in the standard, can be used with both saline and oil as extraction vehicles and provides human-relevant results. Contact our medical device and ISO expert Rose-Marie Jenvert, PhD to learn how GARD can be used in your risk assessment. Customer collaborations to advance non-animal alternatives to sensitization testing SenzaGen and RIFM expanded collaboration on quantitative risk assessment of fragrance materials using GARDskin Dose-Response  View poster Joint poster with Corteva on assessment of agrochemical formulations using GARDskin and GARDpotency       View poster Joint poster with Essity on testing of facial masks using GARDskin Medical Device View poster                     Big pharma screens development candidates with GARDskin Read more Leading cosmetic company tests ingredients with GARDskin Dose-Response to support product safety Read more Expanded in vitro services for skin irritation and corrosion testing Thanks to increasing demand for additional tests to cover more endpoints, SenzaGen expanded its skin toxicology services to include the in vitro skin irritation (OECD 439) and corrosion (OECD 431) assays. The new assays complement our advanced GARD sensitization tests, adding a broader coverage of the skin toxicity mechanisms to our portfolio. Learn more and get a quote New scientific publications Nature Scientific Reports: Quantitative assessment of skin sensitizing potency using GARDskin Dose-Response SenzaGen's paper on GARDskin Dose-Response was published in Nature’s open-access journal Scientific Reports, providing new peer-reviewed evidence that GARD can be used as an in vitro alternative for quantitative potency assessment of skin sensitizers. Read the full publication Cosmetic MDPI: Safety testing of cosmetic products Together with experts from CEHTRA, GenEvolutioN, Laboratoire Watchfrog and PKDerm, we published an article in Cosmetics MDPI, a review of the performance of innovative and efficient in vitro tools for safety testing of cosmetic products and cosmetic ingredients. Read the full publication Upcoming events in 2022 🎧 Webinar in January: Why Choose GARD? More information coming soon 🎧 Webinar in February: Biological Evaluation of Medical Devices More information coming soon Copyright © SenzaGen 2020-2021. All rights reserved. SenzaGen AB | Medicon Village | 223 81 Lund, Sweden You are receiving this email because you expressed interest in SenzaGen's technology in the past. Unsubscribe here if you do not wish to receive technology updates and news from us.